Does Rebif (interferon beta-1a) cause side effects?
Rebif (interferon beta-1a) is a protein produced by recombinant DNA technology using genetically engineered Chinese hamster ovary cells into which the human interferon beta genes have been introduced, used to treat multiple sclerosis (MS).
Rebif is designed to be identical to interferon beta that is naturally produced by various cells in the body. Rebif has antiviral properties and plays a role in regulating the immune response. The exact mechanism by which Rebif works in the body to treat MS is not known.
Rebif does not cure MS. Rather, it helps to decrease the number of flare-ups and slows the occurrence of some of the physical disability that commonly occurs in the disease.
Interferon beta-1a, currently in use to treat multiple sclerosis, and interferon alfa-2b are both under investigation as potential treatments for people with COVID-19 coronavirus disease, the deadly respiratory pandemic caused by the SARS-nCoV-2 virus.
Common side effects of Rebif include
- injection site reactions,
- flu-like symptoms,
- muscle aches,
- diarrhea, and
Serious side effects of Rebif include
- stomach pain,
- increased liver enzymes,
- blood disorders (including a drop in the number of red blood cells, white blood cells, and platelets),
- suicidal thoughts or actions (tell your doctor if this occurs),
- liver disease, and
- serious allergic and skin reactions.
Use of Rebif has not been adequately evaluated in pregnant women. Due to the lack of conclusive safety data, Rebif should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.
What are the important side effects of Rebif (interferon beta-1a)?
The most common side effects of interferon beta-1a are:
- injection site reactions,
- flu-like symptoms,
- muscle aches,
- diarrhea, and
Flu-like symptoms are commonly experienced when patients first start taking interferon beta-1a. These symptoms can be managed with over-the-counter pain and fever reducers, and usually decrease or go away over time.
Stomach pain, an increase in liver enzymes, and blood disorders including a drop in the number of red blood cells, white blood cells, and platelets also may occur.
Rebif (interferon beta-1a) side effects list for healthcare professionals
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
- Infusion-related reactions
- Severe mucocutaneous reactions
- Hepatitis B reactivation with fulminant hepatitis
- Progressive multifocal leukoencephalopathy
- Tumor lysis syndrome
- Cardiovascular adverse reactions
- Renal toxicity
- Bowel obstruction and perforation
Clinical Trials Experience In Lymphoid Malignancies
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data described below reflect exposure to rituximab in 2,783 patients, with exposures ranging from a single infusion up to 2 years. Rituximab was studied in both single-arm and controlled trials (n=356 and n=2,427). The population included 1,180 patients with low grade or follicular lymphoma, 927 patients with DLBCL, and 676 patients with CLL.
Most NHL patients received rituximab as an infusion of 375 mg/m2 per infusion, given as a single agent weekly for up to 8 doses, in combination with chemotherapy for up to 8 doses, or following chemotherapy for up to 16 doses. CLL patients received rituximab 375 mg/m2 as an initial infusion followed by 500 mg/m2 for up to 5 doses, in combination with fludarabine and cyclophosphamide. Seventy-one percent of CLL patients received 6 cycles and 90% received at least 3 cycles of rituximab-based therapy.
The most common adverse reactions of rituximab (incidence ≥25%) observed in clinical trials of patients with NHL were
- infusion-related reactions,
- infection, and
The most common adverse reactions of rituximab (incidence ≥25%) observed in clinical trials of patients with CLL were:
- infusion-related reactions and
In the majority of patients with NHL, infusion-related reactions consisting of
- dizziness, or
- hypertension occurred during the first rituximab infusion.
Infusion-related reactions typically occurred within 30 to 120 minutes of beginning the first infusion and resolved with slowing or interruption of the rituximab infusion and with supportive care (diphenhydramine, acetaminophen, and intravenous saline). The incidence of infusion-related reactions was highest during the first infusion (77%) and decreased with each subsequent infusion.
In patients with previously untreated follicular NHL or previously untreated DLBCL, who did not experience a Grade 3 or 4 infusion-related reaction in Cycle 1 and received a 90-minute infusion of rituximab at Cycle 2, the incidence of Grade 3-4 infusion-related reactions on the day of, or day after the infusion was 1.1% (95% CI [0.3%, 2.8%]). For Cycles 2-8, the incidence of Grade 3- 4 infusion-related reactions on the day of or day after the 90-minute infusion, was 2.8% (95% CI [1.3%, 5.0%]).
Serious infections (NCI CTCAE Grade 3 or 4), including sepsis, occurred in less than 5% of patients with NHL in the single-arm studies. The overall incidence of infections was 31% (bacterial 19%, viral 10%, unknown 6%, and fungal 1%).
In randomized, controlled studies where rituximab was administered following chemotherapy for the treatment of follicular or low-grade NHL, the rate of infection was higher among patients who received rituximab. In diffuse large B-cell lymphoma patients, viral infections occurred more frequently in those who received rituximab.
Cytopenias And Hypogammaglobulinemia
In patients with NHL receiving rituximab monotherapy, NCI-CTC Grade 3 and 4 cytopenias were reported in 48% of patients. These included
The median duration of lymphopenia was 14 days (range, 1-588 days) and of neutropenia was 13 days (range, 2-116 days). A single occurrence of transient aplastic anemia (pure red cell aplasia) and two occurrences of hemolytic anemia following rituximab therapy occurred during the single-arm studies.
In studies of monotherapy, rituximab-induced B-cell depletion occurred in 70% to 80% of patients with NHL. Decreased IgM and IgG serum levels occurred in 14% of these patients.
In CLL trials, the frequency of prolonged neutropenia and late-onset neutropenia was higher in patients treated with rituximab in combination with fludarabine and cyclophosphamide (R-FC) compared to patients treated with FC. Prolonged neutropenia is defined as Grade 3-4 neutropenia that has not resolved between 24 and 42 days after the last dose of study treatment. Late-onset neutropenia is defined as Grade 3-4 neutropenia starting at least 42 days after the last treatment dose.
In patients with previously untreated CLL, the frequency of prolonged neutropenia was 8.5% for patients who received R-FC (n=402) and 5.8% for patients who received FC (n=398). In patients who did not have prolonged neutropenia, the frequency of late-onset neutropenia was 14.8% of 209 patients who received R-FC and 4.3% of 230 patients who received FC.
For patients with previously treated CLL, the frequency of prolonged neutropenia was 24.8% for patients who received R-FC (n=274) and 19.1% for patients who received FC (n=274). In patients who did not have prolonged neutropenia, the frequency of late-onset neutropenia was 38.7% in 160 patients who received R-FC and 13.6% of 147 patients who received FC.
Relapsed Or Refractory, Low-Grade NHL
Adverse reactions presented in Table 1 occurred in 356 patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL treated in single-arm studies of rituximab administered as a single agent. Most patients received rituximab 375 mg/m2 weekly for 4 doses.
Incidence of Adverse Reactions in ≥5% of Patients with Relapsed or Refractory, Low-Grade or Follicular NHL, Receiving Single-agent Rituximab (N=356)a,b
|All Grades (%)||Grade 3 and 4 (%)|
|Any Adverse Reactions||99||57|
|Body as a Whole||86||10|
|Heme and Lymphatic System||67||48|
|Skin and Appendages||44||2|
|Metabolic and Nutritional Disorders||38||3|
|a Adverse reactions observed up to 12 months following rituximab.|
b Adverse reactions graded for severity by NCI-CTC criteria.
In these single-arm rituximab studies, bronchiolitis obliterans occurred during and up to 6 months after rituximab infusion.
Previously Untreated, Low-Grade Or Follicular, NHL
In NHL Study 4, patients in the R-CVP arm experienced a higher incidence of infusional toxicity and neutropenia compared to patients in the CVP arm. The following adverse reactions occurred more frequently (≥5%) in patients receiving R-CVP compared to CVP alone:
- rash (17% vs. 5%),
- cough (15% vs. 6%),
- flushing (14% vs. 3%),
- rigors (10% vs. 2%),
- pruritus (10% vs. 1%),
- neutropenia (8% vs. 3%), and
- chest tightness (7% vs. 1%).
In NHL Study 5, detailed safety data collection was limited to serious adverse reactions, Grade ≥2 infections, and Grade ≥3 adverse reactions. In patients receiving rituximab as single-agent maintenance therapy following rituximab plus chemotherapy, infections were reported more frequently compared to the observation arm (37% vs. 22%).
Grade 3-4 adverse reactions occurring at a higher incidence (≥2%) in the rituximab group were
- infections (4% vs. 1%) and
- neutropenia (4% vs. <1%).
In NHL Study 6, the following adverse reactions were reported more frequently (≥5%) in patients receiving rituximab following CVP compared to patients who received no further therapy:
- fatigue (39% vs. 14%),
- anemia (35% vs. 20%),
- peripheral sensory neuropathy (30% vs. 18%),
- infections (19% vs. 9%),
- pulmonary toxicity (18% vs. 10%),
- hepato-biliary toxicity (17% vs. 7%),
- rash and/or pruritus (17% vs. 5%),
- arthralgia (12% vs. 3%), and
- weight gain (11% vs. 4%).
Neutropenia was the only Grade 3 or 4 adverse reaction that occurred more frequently (=2%) in the rituximab arm compared with those who received no further therapy (4% vs. 1%).
In NHL Studies 7 (NCT00003150) and 8, the following adverse reactions, regardless of severity, were reported more frequently (≥5%) in patients age ≥60 years receiving R-CHOP as compared to CHOP alone:
- pyrexia (56% vs. 46%),
- lung disorder (31% vs. 24%),
- cardiac disorder (29% vs. 21%), and
- chills (13% vs. 4%).
Detailed safety data collection in these studies was primarily limited to Grade 3 and 4 adverse reactions and serious adverse reactions.
In NHL Study 8, a review of cardiac toxicity determined that supraventricular arrhythmias or tachycardia accounted for most of the difference in cardiac disorders (4.5% for R-CHOP vs. 1.0% for CHOP).
The following Grade 3 or 4 adverse reactions occurred more frequently among patients in the R-CHOP arm compared with those in the CHOP arm:
- thrombocytopenia (9% vs. 7%) and
- lung disorder (6% vs. 3%).
Other Grade 3 or 4 adverse reactions occurring more frequently among patients receiving R-CHOP were viral infection (NHL Study 8), neutropenia (NHL Studies 8 and 9 (NCT00064116)), and anemia (NHL Study 9).
The data below reflect exposure to rituximab in combination with fludarabine and cyclophosphamide in 676 patients with CLL in CLL Study 1 (NCT00281918) or CLL Study 2 (NCT00090051). The age range was 30-83 years and 71% were men. Detailed safety data collection in CLL Study 1 was limited to Grade 3 and 4 adverse reactions and serious adverse reactions.
Infusion-related adverse reactions were defined by any of the following adverse events occurring during or within 24 hours of the start of infusion: nausea, pyrexia, chills, hypotension, vomiting, and dyspnea.
In CLL Study 1, the following Grade 3 and 4 adverse reactions occurred more frequently in R-FC-treated patients compared to FC-treated patients:
- infusion-related reactions (9% in R-FC arm),
- neutropenia (30% vs. 19%),
- febrile neutropenia (9% vs. 6%),
- leukopenia (23% vs. 12%), and
- pancytopenia (3% vs. 1%).
In CLL Study 2, the following Grade 3 or 4 adverse reactions occurred more frequently in R-FC-treated patients compared to FC-treated patients:
- infusion-related reactions (7% in R-FC arm),
- neutropenia (49% vs. 44%),
- febrile neutropenia (15% vs. 12%),
- thrombocytopenia (11% vs. 9%),
- hypotension (2% vs. 0%), and
- hepatitis B (2% vs. <1%).
Fifty-nine percent of R-FC-treated patients experienced an infusion-related reaction of any severity.
Clinical Trials Experience In Granulomatosis With Polyangiitis (GPA) (Wegener’s Granulomatosis) And Microscopic Polyangiitis (MPA)
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Induction Treatment Of Adult Patients With Active GPA/MPA (GPA/MPA Study 1)
The data presented below from GPA/MPA Study 1 (NCT00104299) reflect the experience in 197 adult patients with active GPA and MPA treated with rituximab or cyclophosphamide in a single controlled study, which was conducted in two phases: a 6 month randomized, double-blind, double-dummy, active-controlled remission induction phase and an additional 12 month remission maintenance phase.
In the 6-month remission induction phase, 197 patients with GPA and MPA were randomized to either rituximab 375 mg/m2 once weekly for 4 weeks plus glucocorticoids, or oral cyclophosphamide 2 mg/kg daily (adjusted for renal function, white blood cell count, and other factors) plus glucocorticoids to induce remission.
Once remission was achieved or at the end of the 6 month remission induction period, the cyclophosphamide group received azathioprine to maintain remission. The rituximab group did not receive additional therapy to maintain remission. The primary analysis was at the end of the 6 month remission induction period and the safety results for this period are described below.
Adverse reactions presented below in Table 2 were adverse events which occurred at a rate of greater than or equal to 10% in the rituximab group. This table reflects experience in 99 GPA and MPA patients treated with rituximab, with a total of 47.6 patient-years of observation and 98 GPA and MPA patients treated with cyclophosphamide, with a total of 47.0 patient-years of observation. Infection was the most common category of adverse events reported (47-62%) and is discussed below.
Incidence of All Adverse Reactions Occurring in ≥10% of Rituximab-treated Patients with active GPA and MPA in the GPA/MPA Study 1 Up to Month 6*
|Nausea||18 (18%)||20 (20%)|
|Diarrhea||17 (17%)||12 (12%)|
|Headache||17 (17%)||19 (19%)|
|Muscle spasms||17 (17%)||15 (15%)|
|Anemia||16 (16%)||20 (20%)|
|Peripheral edema||16 (16%)||6 (6%)|
|Insomnia||14 (14%)||12 (12%)|
|Arthralgia||13 (13%)||9 (9%)|
|Cough||13 (13%)||11 (11%)|
|Fatigue||13 (13%)||21 (21%)|
|Increased ALT||13 (13%)||15 (15%)|
|Hypertension||12 (12%)||5 (5%)|
|Epistaxis||11 (11%)||6 (6%)|
|Dyspnea||10 (10%)||11 (11%)|
|Leukopenia||10 (10%)||26 (27%)|
|Rash||10 (10%)||17 (17%)|
|* The study design allowed for crossover or treatment by best medical judgment, and 13 patients in each treatment group received a second therapy during the 6 month study period.|
- Infusion-related reactions in GPA/MPA Study 1 were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators.
- Among the 99 patients treated with rituximab, 12% experienced at least one infusion-related reaction, compared with 11% of the 98 patients in the cyclophosphamide group.
- Infusion-related reactions included cytokine release syndrome, flushing, throat irritation, and tremor. In the rituximab group, the proportion of patients experiencing an infusion-related reaction was 12%, 5%, 4%, and 1% following the first, second, third, and fourth infusions, respectively.
- Patients were pre-medicated with antihistamine and acetaminophen before each rituximab infusion and were on background oral corticosteroids which may have mitigated or masked an infusion-related reaction; however, there is insufficient evidence to determine whether premedication diminishes the frequency or severity of infusion-related reactions.
In GPA/MPA Study 1, 62% (61/99) of patients in the rituximab group experienced an infection of any type compared to 47% (46/98) patients in the cyclophosphamide group by Month 6.
The most common infections in the rituximab group were
The incidence of serious infections was 11% in the rituximab-treated patients and 10% in the cyclophosphamide treated patients, with rates of approximately 25 and 28 per 100 patient-years, respectively. The most common serious infection was pneumonia.
Hypogammaglobulinemia (IgA, IgG or IgM below the lower limit of normal) has been observed in patients with GPA and MPA treated with rituximab in GPA/MPA Study 1. At 6 months, in the rituximab group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline, had low IgA, IgG and IgM levels, respectively compared to 25%, 50%, and 46% in the cyclophosphamide group.
Follow Up Treatment Of Adult Patients With GPA/MPA Who Have Achieved Disease Control With Induction Treatment (GPA/MPA Study 2)
In GPA/MPA Study 2 (NCT00748644), an open-label, controlled, clinical study, evaluating the efficacy and safety of non-U.S.-licensed rituximab versus azathioprine as follow up treatment in adult patients with GPA, MPA or renal-limited ANCA-associated vasculitis who had achieved disease control after induction treatment with cyclophosphamide, a total of 57 GPA and MPA patients in disease remission received follow up treatment with two 500 mg intravenous infusions of non-U.S.-licensed rituximab, separated by two weeks on Day 1 and Day 15, followed by a 500 mg intravenous infusion every 6 months for 18 months.
The safety profile was consistent with the safety profile for rituximab in GPA and MPA.
In GPA/MPA Study 2, 7/57 (12%) patients in the non-U.S.-licensed rituximab arm reported infusion-related reactions. The incidence of IRR symptoms was highest during or after the first infusion (9%) and decreased with subsequent infusions (<4%). One patient had two serious IRRs, two IRRs led to a dose modification, and no IRRs were severe, fatal, or led to withdrawal from the study.
In GPA/MPA Study 2, 30/57 (53%) patients in the non-U.S.-licensed rituximab arm and 33/58 (57%) in the azathioprine arm reported infections. The incidence of all grade infections was similar between the arms. The incidence of serious infections was similar in both arms (12%). The most commonly reported serious infection in the group was mild or moderate bronchitis.
Long-Term, Observational Study With Rituximab In Patients With GPA/MPA (GPA/MPA Study 3)
In a long-term observational safety study (NCT01613599), 97 patients with GPA or MPA received treatment with rituximab (mean of 8 infusions [range 1-28]) for up to 4 years, according to physician standard practice and discretion. Majority of patients received doses ranging from 500 mg to 1,000 mg, approximately every 6 months. The safety profile was consistent with the safety profile for rituximab in GPA and MPA.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other rituximab products may be misleading.
Using an ELISA assay, anti-rituximab antibody was detected in 4 of 356 (1.1%) patients with low-grade or follicular NHL receiving single-agent rituximab. Three of the four patients had an objective clinical response.
A total of 23/99 (23%) rituximab-treated adult patients with GPA and MPA developed anti-rituximab antibodies by 18 months in GPA/MPA Study 1. The clinical relevance of anti-rituximab antibody formation in rituximabtreated adult patients is unclear.
The following adverse reactions have been identified during post-approval use of rituximab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Hematologic: prolonged pancytopenia, marrow hypoplasia, Grade 3-4 prolonged or late-onset neutropenia, hyperviscosity syndrome in Waldenstrom's macroglobulinemia, prolonged hypogammaglobulinemia.
- Cardiac: fatal cardiac failure.
- Immune/Autoimmune Events: uveitis, optic neuritis, systemic vasculitis, pleuritis, lupus-like syndrome, serum sickness, polyarticular arthritis, and vasculitis with rash.
- Infection: viral infections, including progressive multifocal leukoencephalopathy (PML), increase in fatal infections in HIV-associated lymphoma, and a reported increased incidence of Grade 3 and 4 infections.
- Neoplasia: disease progression of Kaposi’s sarcoma.
- Skin: severe mucocutaneous reactions, pyoderma gangrenosum (including genital presentation).
- Gastrointestinal: bowel obstruction and perforation.
- Pulmonary: fatal bronchiolitis obliterans and fatal interstitial lung disease.
- Nervous system: Posterior Reversible Encephalopathy Syndrome (PRES)/Reversible Posterior Leukoencephalopathy Syndrome (RPLS).
What drugs interact with Rebif (interferon beta-1a)?
- Formal drug interaction studies have not been performed with rituximab products.
- In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide.
- In clinical trials of patients with another indication, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab.
Rebif (interferon beta-1a) is a protein produced by recombinant DNA technology using genetically engineered Chinese hamster ovary cells into which the human interferon beta genes have been introduced, used to treat multiple sclerosis (MS). Common side effects of Rebif include injection site reactions, flu-like symptoms, headache, muscle aches, nausea, pain, fever, diarrhea, and infections. Use of Rebif has not been adequately evaluated in pregnant women. It is unknown if Rebif is excreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
Novel Coronavirus (COVID-19) Prevention: Frequently Asked Questions
Why is coronavirus considered dangerous? What are symptoms you should look for? Take this quiz to learn how to protect yourself.
Coronavirus COVID-19 Prevention: Test Your Medical IQ
What's really the best way to prevent the spread of new coronavirus COVID-19? Should wear a mask or not? Take this quiz to find...
Multiple Sclerosis (MS) Quiz: Test Your Medical IQ
Multiple Sclerosis is a debilitating neurological condition. Take the MS Quiz to test your knowledge of the causes, symptoms,...
Picture of Multiple Sclerosis Symptoms
Symptoms of multiple sclerosis may be single or multiple and may range from mild to severe in intensity and short to long in...
Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases
Learn to spot and treat skin conditions commonly found in adults such as acne, Covid-19 rashes, eczema, shingles, psoriasis,...
Multiple Sclerosis (MS) Symptoms and Treatment
Learn about multiple sclerosis (MS) causes, symptoms, and treatment for this autoimmune disease that attacks the nerves of the...
What You Should Know About Multiple Sclerosis
Learn about celebrities, such as Montel Williams and Jack Osbourne, who are living with multiple sclerosis.
Multiple Sclerosis: Making an MS Friendly Home
Adults with multiple sclerosis may be at risk for injuries, hazards, and falling at home. Some simple home modifications can...
Coronavirus COVID-19 (SARS-CoV-2) Pandemic Outbreak: What You Need to Know
A new strain of coronavirus (COVID-19, SARS-CoV-2) was reported from Wuhan, China in December, 2019. This outbreak of respiratory...
Coronavirus COVID-19 (SARS-CoV-2): The Latest News, Updates and Information
See the latest news updates and information on the Coronavirus COVID-19 outbreak. Learn about symptoms, prevention, possible...
What Drugs May Fight COVID-19? Drug Trials, Treatments, Vaccines
What drugs could help fight coronavirus COVID-19? Clinical studies are ongoing for antiviral drugs like hydroxychloroquine,...
Related Disease Conditions
Multiple Sclerosis (MS) Symptoms, Causes, Treatment, Life Expectancy
Multiple sclerosis or MS is an autoimmune disorder in which brain and spinal cord nerve cells become demyelinated. This damage results in symptoms that may include numbness, weakness, vertigo, paralysis, and involuntary muscle contractions. Different forms of MS can follow variable courses from relatively benign to life-threatening. MS is treated with disease-modifying therapies. Some MS symptoms can be treated with medications.
Alternative Treatment for MS (CAM for MS)
The term alternative therapy, in general, is used to describe any medical treatment or intervention that has not been scientifically documented or identified as safe or effective for a specific condition. Alternative therapy encompasses a variety of disciplines that range from diet and exercise to mental conditioning to lifestyle changes.
Multiple Sclerosis (MS)
Multiple sclerosis (MS) symptoms vary from person to person, and can last for days to months without periods of remission. Symptoms of MS include sexual problems and problems with the bowel, bladder, eyes, muscles, speech, swallowing, brain, and nervous system. The early symptoms and signs of multiple sclerosis usually start between age 20 and 40. MS in children, teens, and those over age 40 is rare. Treatment options for multiple sclerosis vary depending on the type and severity of symptoms. Medications may be prescribed to manage MS symptoms.
Is MS Contagious? (Multiple Sclerosis)
Multiple sclerosis, or MS, is a degenerative disease of the covering around the nerves in the central nervous system (CNS). Researchers and doctors don't know the exact cause, but many theorize that it may be due to environmental triggers, an autoimmune disease, and viruses (infections). Symptoms of MS include vision changes, paralysis, vertigo, heat intolerance, slurred speech, sexual dysfunction, and urinary incontinence (the inability to urinate). There's no vaccine or cure for MS, but the progression and symptoms of the disease can be treated.
MS (Multiple Sclerosis) vs. ALS (Amyotrophic Lateral Sclerosis) Differences and Similarities
ALS (amyotrophic lateral sclerosis, Lou Gehrig's disease) and MS (multiple sclerosis) are both diseases of the nervous system (neurodegenerative). ALS is a disease in which the nerve cells in the body are attacked by the immune system, although it's not considered an autoimmune disease by some scientists. MS is an autoimmune disease in which the insulated covering of the nerves (myelin sheath) in the CNS (central nervous system) degenerate, or deteriorate. Scientists don't know the exact cause of either problem. However, they have discovered that mutations in the gene that produces the SOD1 enzyme were associated with some cases of familial ALS. Scientists also theorize that multiple sclerosis may be caused by infection or vitamin D deficiency. ALS occurs between 50-70 years of age (the average age of occurrence ALS is 55), and mostly affects men. While MS occurs between 20-60 years of age, and mostly affects women. About 30,000 people in the US have ALS, and an average of 5,000 new diagnoses per year (that's about 15 new cases per week). Worldwide, MS affects more than 2.3 million people, with about 10,000 new cases diagnosed each year (that's about 200 new diagnoses per week).Some of the signs and symptoms of both diseases include muscle weakness, muscle spasms, problems walking, fatigue, slurred speech, and problems swallowing. ALS signs and symptoms that are different from MS include problems holding the head upright, clumsiness, muscle cramps and twitches, problems holding objects, and uncontrollable periods of laughing or crying. MS signs and symptoms that are different from ALS include vision problems, vertigo and balance problems, sexual problems, memory problems, depression, mood swings, and digestive problems. There is no cure for either disease, however the prognosis and life expectancy are different. Multiple sclerosis is not a fatal condition, while ALS progresses rapidly and leads to death.
Multiple Sclerosis (MS) and Pregnancy
Multiple sclerosis or MS is a central nervous system disease in which the immune system attacks the myelin sheath (the protective coating around nerves). Symptoms of MS include pain, sexual problems, fatigue, numbness and tingling, emotional changes, and depression.Women who are pregnant and have multiple sclerosis may have more difficulty carrying a pregnancy. Multiple sclerosis does not affect ability to conceive, and does not seem to affect fertility. MS symptoms during pregnancy may stay the same or get better; however, they may worsen after giving birth. Pregnancy decreases the number of relapses, but flares increase in the first 3-6 months after delivery. Pregnant women with MS may carrying a pregnancy more difficult to tell when labor starts, and there is an increased need to use forceps or vacuum to assist with delivery or b7 C-section (Cesarean birth) increases. Some treatment MS drugs may be safe to use during pregnancy; however, some drugs should not be taken, for example, baclofen (Gablofen, Lioresal), fluoxetine (Prozac, Sarafem), or solifenacin succinate (VESIcare), and most disease-modifying therapies (DMTs). Talk with your healthcare team about vitamins, supplements, and medications that you are taking if you are pregnant and have MS.
Multiple Sclerosis (MS) Early Warning Signs and Types
Multiple sclerosis (MS) can be thought of as an immune-mediated inflammatory process involving different areas of the central nervous system (CNS) at various points in time. Early warning signs and symptoms of MS in children, teens, and adults are similar; however, children and teens with pediatric also may have seizures and a complete lack of energy. Adults with MS do not have these signs and symptoms. Other signs and symptoms of MS include inflammation of the optic nerve (optic neuritis), changes in vision, Wiping or having tissues around the eye and moving the eye may be painful, and double vision. There are four types of MS, relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive relapsing MD (PRMS).
COVID-19 (Coronavirus, 2019-nCoV)
Infection with COVID-19 (2019 novel coronavirus, 2019-nCoV) causes respiratory problems in humans. Transmission of COVID-19 occurs mainly through contact with respiratory sections from an infected person, however, fecal contamination may also spread the virus. Symptoms start off flu-like and progress to coughing, fever, shortness of breath, shaking chills, headache, loss of sense of taste and/or smell, muscle pain, and sore throat. Treatment focuses on supportive care and symptom relief.
COVID-19 (Coronavirus) Prevention Tips
COVID-19 is a novel coronavirus that spreads from person to person via infected respiratory droplets. The main symptoms of COVID-19 infection include cough, fever, and shortness of breath. Occasionally, people infected with COVID-19 may experience diarrhea, a sore throat, a runny or stuffy nose, or aches and pains. Avoiding contact with infected people, social distancing, not touching your face, frequent hand washing, cleaning, and disinfecting of frequently touched surfaces can help to reduce your risk of contracting the 2019 novel coronavirus.
COVID-19 vs. Flu vs. Cold
When you're feeling sick, it can be difficult to distinguish the symptoms of a COVID-19 infection from the symptoms of the common cold or the flu (influenza). While fever is common with the flu and COVID-19, sneezing is typically only associated with colds. Though sore throats are typical with colds, they are uncommon with COVID-19 infections and the flu.
COVID-19 vs. Allergies
Though there is some overlap in allergy and COVID-19 signs and symptoms there are also significant differences. Symptoms that they have in common include headache, fatigue, tiredness, shortness of breath, wheezing, and sore throat. Fever does not occur with allergies but is one of the defining symptoms of COVID-19 infections.
Can Stress Cause Multiple Sclerosis (MS)?
Multiple sclerosis (MS) results when your immune system attacks the cells of the brain and spinal cord. It is an autoimmune disease, a condition in which the body’s immune system is misdirected and attacks its own cells. Stress can make it difficult for a person to manage MS symptoms. Regular exercise and mindful eating have been found to control the stress levels and overall health of people with MS.
What Are the Very First Signs of Multiple Sclerosis?
Multiple sclerosis (MS) is an inflammatory, neurodegenerative, and autoimmune disease that affects the brain and spinal cord of the central nervous system (CNS). MS is one of the most common causes of non-injurious disability in young and middle-aged adults.
What Are the Early Signs of Multiple Sclerosis?
Multiple sclerosis is an autoimmune disease in which the immune system attacks the central nervous system (spinal cord and brain) by damaging and destroying the protective myelin sheath around the nerve fibers. Someone with multiple sclerosis might develop problems with muscle control, vision, bladder control and other body functions.
Does COVID-19 Affect My Heart?
As per the American Heart Association, COVID-19 may have a long-term effect on the heart. Having a heart condition doesn't make a person more likely to catch COVID-19, but an individual with heart disease or a serious heart condition is more likely to become severely ill from COVID-19 and has a higher risk of death.
Treatment & Diagnosis
- Multiple Sclerosis MS FAQs
- Wuhan Coronavirus FAQs
- Coronavirus COVID-19 Prevention FAQs
- What Are Serum Antibody Treatments for COVID-19 Coronavirus?
- Testing Is Key to COVID-19 Recovery for Patients and Economy
- Should I Go to the Dentist During the COVID-19 Pandemic?
- Is the Test for COVID-19 Coronavirus Reliable?
- What if I get COVID-19 with Rheumatoid Arthritis?
- How Long Can the COVID-19 Coronavirus Survive?
- What if I get COVID-19 with Diabetes?
- What if I Get COVID-19 with Asthma?
- Multiple Sclerosis: New Treatment Possibility for MS
- Multiple Sclerosis: New Multiple Sclerosis Treatment Suspended
- How Serious Is Multiple Sclerosis?
- How Does Multiple Sclerosis Affect the Body?
- Multiple Sclerosis Treatment
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.